Aztreonam-d6 is intended for use as an internal standard for the quantification of aztreonam (Item No. 19784) by GC- or LC-MS. Aztreonam is a synthetic β-lactam antibiotic of the monobactam class.{31705} It is active against clinical isolates of E. coli, S. marcescens, P. aeruginosa, Klebsiella species, Proteus species, and Enterobacter species (MICs = S. pneumoniae, B. fragilis, and S. faecalis (MICs = >100 µg/ml for all). It interferes with peptidoglycan synthesis in the bacterial cell wall of the Gram-negative bacteria E. coli, P. vulgaris, E. cloacae, K. pneumoniae, and P. aeruginosa by inhibiting penicillin-binding protein 3 (PBP3; IC100 = 0.1 µg/ml for all). It increases survival in mice with systemic Gram-negative bacterial infections (ED50s = 0.1-24.7 mg/kg). Formulations containing aztreonam have been used in the treatment of P. aeruginosa infections in individuals with cystic fibrosis.
Available on backorder
An internal standard for the quantification of aztreonam by GC- or LC-MS,
Formal name: 2-[[(Z)-[1-(2-amino-4-thiazolyl)-2-[[(2S,3S)-2-methyl-4-oxo-1-sulfo-3-azetidinyl]amino]-2-oxoethylidene]amino]oxy]-2-(methyl-d3)-propanoic-3,3,3-d3 acid
Synonyms: SQ 26,776-d6
Molecular weight: 441.5
CAS: 1127452-94-1
Purity: ≥99% deuterated forms (d1-d6)
Formulation: A solid
Cyclin-dependent kinases (CDKs) are key regulators of cell cycle progression and are therefore promising targets for cancer therapy. (R)-Roscovitine is a potent inhibitor of Cdk2/cyclin E with an IC50 value of 0.1 µM.{14988} It also inhibits Cdk7/cyclin H, Cdk5/p35, and cell division cycle (cdc)/cyclin B with IC50 values of 0.49, 0.16, and 0.65 µM, respectively.{14987,14988,14991} (R)-Roscovitine inhibits the growth of rapidly proliferating cells with an average IC50 value of 15.2 µM against a panel of 19 human tumor cell lines.{14988} In murine models of polycystic kidney disease, (R)-roscovitine effectively inhibited disease progression at doses of 50-100 mg/kg.{14564}
Available on backorder
1,2-Dipalmitoyl-sn-glycero-3-PC (DPPC) is a zwitterionic glycerophospholipid commonly used in the formation of lipid monolayers, bilayers, and liposomes for use in a variety of applications.{14480,24261,14478,14479} It has been used in the formation of proteoliposomes for implantation of γ-glutamyl transpeptidase into human erythrocyte membranes.{14478} Incorporation of glycosphingolipid antigens into DPPC-containing liposomes increases the immunogenicity of the antigens in mice.{14479}
Available on backorder
Cyclin-dependent kinases (CDKs) are key regulators of cell cycle progression and are therefore promising targets for cancer therapy. (R)-Roscovitine is a potent inhibitor of Cdk2/cyclin E with an IC50 value of 0.1 µM.{14988} It also inhibits Cdk7/cyclin H, Cdk5/p35, and cell division cycle (cdc)/cyclin B with IC50 values of 0.49, 0.16, and 0.65 µM, respectively.{14987,14988,14991} (R)-Roscovitine inhibits the growth of rapidly proliferating cells with an average IC50 value of 15.2 µM against a panel of 19 human tumor cell lines.{14988} In murine models of polycystic kidney disease, (R)-roscovitine effectively inhibited disease progression at doses of 50-100 mg/kg.{14564}
Available on backorder
The nuclear factor-κB (NF-κB) regulates the expression of numerous genes involved in immunity and inflammation, cellular stress responses, growth, and apoptosis. Resveratrol, a polyphenolic trans-stilbene, is a known inhibitor of the activation of NF-κB and exhibits activity against a wide variety of cancer cells. CAY10512 is a substituted trans-stilbene analog of resveratrol that is 100-fold more potent as measured by antioxidant activity. The IC50 value for inhibition of TNFα-induced activation of NF-κB by CAY10512 is 0.15 µM compared to 20 µM by resveratrol.{14545}
Available on backorder